November 14th, 2021
Sunday
18:00
GMT
Free
Registration is required
Certification
To all attendants via email
“November 14th, 2021 at 18:00 GMT”
New York
13:00
GMT/London
18:00
Athens
20:00
San Diego
10:00
CEST/Paris, Rome
19:00
Beijing
02:00 (15/11)
The Webinar continues the series of MSc Webinars – the online-ZOOM events for the clinicians and educators in the field of psychiatry.
The MSc Webinar is organized for mental health professionals by the Faculty of Medicine, School of Health Sciences and Medical School of the Aristotle University of Thessaloniki, under the auspices of:
WPA 2020-23 Action Plan group on Evidence Based Psychopharmacology
WPA section on Evidence Based Psychiatry
The aim of these educational sessions is to provide a global and comprehensive update of the newest developments in neurobiology, psychopharmacology, treatment guidelines and personcentered care of mental disorders.
The strategic approach of the invited speakers is to avoid content-free eloquence and authority and to face hard questions on the base of research findings.
SPEAKERS
Prof. Darrel Regier
M.D., M.P.H.
"The interaction of psychiatric classification and epidemiology development"
Dr. Regier is currently a Senior Scientist at the Center for the Study of Traumatic Stress, in the Henry M Jackson Foundation for the Advancement of Military Medicine, and Adjunct Professor in Psychiatry, Department of Psychiatry, Uniformed Services University of the Health Sciences in Bethesda, Maryland. He also serves as an independent senior scientific consultant to the American Psychiatric Association (APA) on DSM-5 and research related issues.
In March 2014, he completed 14 years as APA’s Research Director and also as Director of the American Psychiatric Institute for Research and Education (APIRE). A principal responsibility was to coordinate the maintenance and revision plans for the APA’s fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In 2006, he was named Vice-Chair of the DSM-5 Task Force to work jointly with the Task Force Chair, Dr. David Kupfer--DSM-5 was published in May 2013.Dr. Regier completed 25 years at the National Institute of Mental Health (NIMH) in 2000, during which time he directed three research divisions in the areas of epidemiology, prevention, clinical research, and health services research. He initiated the national development of mental disorder prevalence and service use surveys, including the Epidemiologic Catchment Area (ECA) program, mental health service use in primary care and specialty settings, the organization and financing of such services, and international programs on the classification of mental disorders with the World Health Organization. He served as the Scientific Coordinator/Director for four National Advisory Mental Health Council reports to Congress on mental health insurance parity that resulted in the Federal Employees Health Benefit (FEHB) mental health parity benefit in 2001. The FEHB and additional directed APIRE research on parity were instrumental in passage of the U.S. national Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
Prof. Roger McIntyre
M.D., FRCPC
"Biological Models for Mental Disorders"
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.
Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE) and the CEO of Braxia Scientific Corp.
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 750 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Organization
MSC ‘CLINICAL MENTAL HEALTH’
SCHOOL OF MEDICINE
FACULTY OF HEALTH SCIENCES
ARISTOTLE UNIVERSITY OF THESSALONIKI GREECE
In collaboration with
WPA 2020-23 Action Plan group on Evidence Based Psychopharmacology
WPA section on Evidence Based Psychiatry
